C3 Glomerulonephritis: A Case Report and Literature Review
Article Sidebar
Main Article Content
Abstract
Membranoproliferative glomerulitis is a characteristic pathological finding in several systemic diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, and plasma cell dyscrasia. The malfunction of C3 complement system causing the uncommon nephritic syndrome called C3 glomerulonephritis is also associated with pathological changes which are characteristic of membranoproliferative glomerulonephritis. High clinical suspicion and kidney biopsy are required to make a diagnosis of C3 glomerulonephritis. Like other glomerulonephritis, prompt treatment with immunosuppression can improve renal outcome. This is a report a 73-year-old man presenting with rash on both feet and acute kidney injury with nephritic urine sediments. The results of kidney biopsy were compatible with C3 glomerulonephritis. Further testing with serum immunofixation
was not suggestive of monoclonal gammopathy, which is commonly associated with this condition in patients older than 50 years.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under CC BY-NC-ND 4.0 license, which allows for non-commercial reuse of the published paper as long as the published paper is fully attributed. Anyone can share (copy and redistribute) the material in any medium or format without having to ask permission from the author or the Nephrology Society of Thailand.
References
Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018;93(4):977–85.
Medjeral-Thomas NR, O’Shaughnessy MM, O’Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 Glomerulopathy: Clinicopathologic Features and Predictors of Outcome. Clin J Am Soc Nephrol. 2014;9(1):46–53.
Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: Ten Years’ Experience at Mayo Clinic. Mayo Clin Proc. 2018;93(8):991–1008.
Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012;82(4):465–73.
Servais A, Noël L-H, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey M-A, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454–64.
Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016;71:131–42.
Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015;88(5):1153–60.
Viswanathan GK, Nada R, Kumar A, Ramachandran R, Rayat CS, Jha V, et al. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience. Diagn Pathol. 2015;10(1):6.
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1–276.
Zand L, Kattah A, Fervenza FC, Smith RJH, Nasr SH, Zhang Y, et al. C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series. Am J Kidney Dis. 2013;62(3):506–14.
Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int. 2018;94(1):178–86.
Li L-L, Li Z-Y, Wang S-X, Yu X-J, Tan Y, Wang Y, et al. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis. BMC Nephrol. 2019;20(1):459.
Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, et al. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. Clin J Am Soc Nephrol. 2018;13(3):406–13.
Le Quintrec M, Lapeyraque A-L, Lionet A, Sellier-Leclerc A-L, Delmas Y, Baudouin V, et al. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. Am J Kidney Dis. 2018;72(1):84–92.
Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, et al. Clinical Findings, Pathology, and Outcomes of C3GN after Kidney Transplantation. J Am Soc Nephrol. 2014;25(5):1110–7.214